Gyrodyne , LLC (NASDAQ:GYRO) Short Interest Down 37.5% in March

Gyrodyne , LLC (NASDAQ:GYRO) was the target of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 45 shares, a decline of 37.5% from the February 26th total of 72 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 798 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GYRO. Advisory Services Network LLC acquired a new position in shares of Gyrodyne during the third quarter valued at $77,000. Susquehanna International Group LLP acquired a new stake in Gyrodyne in the third quarter worth about $142,000. Teton Advisors LLC bought a new position in Gyrodyne in the 3rd quarter valued at about $177,000. Finally, Bulldog Investors LLP acquired a new position in Gyrodyne during the 3rd quarter valued at about $601,000. Institutional investors own 71.36% of the company’s stock.

Gyrodyne Stock Performance

GYRO stock traded down $0.40 on Friday, reaching $7.78. The company’s stock had a trading volume of 1,221 shares, compared to its average volume of 2,358. Gyrodyne has a 52 week low of $6.80 and a 52 week high of $12.00. The firm has a fifty day moving average of $8.71 and a two-hundred day moving average of $9.34.

About Gyrodyne

Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.

The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.